The goal of the Cellular Therapeutics Clinic (CTC) at Memorial Sloan Kettering Cancer Center is to treat cancer patients with a novel therapeutic approach utilizing immune cells called T cells. These T cells are modified in the laboratory to express artificial receptors, called chimeric antigen receptors (CARs), which enable the resulting CAR T cells to recognize and kill tumor cells.
Our institution has pioneered this novel cell-based immune approach to treating patients with B cell cancers, including leukemias and lymphomas. In studies of these treatments, we have demonstrated remarkable antitumor responses in patients treated with CAR T cells. We are currently expanding this CAR T cell therapeutic approach to a wider array of cancer types, with a goal of expanding this technology successfully to solid tumors such as ovarian cancer, prostate cancer, mesothelioma, and certain types of breast cancer.
Patients are referred to the CTC by medical oncologists from outside institutions as well as at Memorial Sloan Kettering. If you decide to participate in a clinical trial within the CTC, the clinic's physicians and nurses will care for you during the time you are participating in the study. Once your participation is complete, you will return to your regular medical oncologist for ongoing care.
If you commit to being in a clinical trial in the CTC, please understand that your participation requires very specific appointment schedules. There may be times when you are asked to stay close to Memorial Sloan Kettering. Some appointments cannot be changed or delayed. Please check with the clinical trial staff before scheduling any vacations or other time away. We will help you coordinate your plans.